Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxVRCDF -60.53% 3-Year EPS without NRI Growth Rate is 50.30% as of Dec. 2025, which is 37% above its 10-year median of 36.70. The stock has 3 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, Verici Dx ranks better than 85% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 50.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Verici Dx was 50.30% per year. The lowest was 23.10% per year. And the median was 36.70% per year.
Verici Dx (OTCPK:VRCDF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Verici Dx 3-Year EPS without NRI Growth Rate Related Terms
VRCDF vs TMO, DHR, NTRA: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Verici Dx's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Verici Dx's 3-Year EPS without NRI Growth Rate falls into.
Verici Dx 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 50.30% mean?
Verici Dx (VRCDF) has a 3-Year EPS without NRI Growth Rate of 50.30% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Verici Dx and its competitors. This is 37% above median its historical median of 36.70. Over the past decade, Verici Dx's 3-Year EPS without NRI Growth Rate has ranged from 23.10 to 50.30. According to the industry distribution chart, Verici Dx ranks #24 out of 160 companies in the Medical Diagnostics & Research industry, placing it in the top 15%.
Is Verici Dx's 3-Year EPS without NRI Growth Rate too high?
Verici Dx's current 3-Year EPS without NRI Growth Rate of 50.30% is 37% above median its 10-year median of 36.70. Over the past 10 years, this metric has ranged from a low of 23.10 to a high of 50.30. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 11.85. Verici Dx's value of 50.30% is 324.5% above this industry median. Based on the distribution chart, Verici Dx ranks #24 out of 160 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Verici Dx's 3-Year EPS without NRI Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #24 out of 160 companies for 3-Year EPS without NRI Growth Rate. This places Verici Dx in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 11.85. Verici Dx's value of 50.30% is 324.5% above this benchmark. Historically, Verici Dx's own 3-Year EPS without NRI Growth Rate has ranged from 23.10 to 50.30 over the past decade. While the company's 10-year median is 36.70 vs. the industry median of 11.85, Verici Dx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 11.85, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verici Dx's current 3-Year EPS without NRI Growth Rate of 50.30% is 324.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 11.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current 3-Year EPS without NRI Growth Rate is 50.30%, which is 37% above median its own 10-year median of 36.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current 3-Year EPS without NRI Growth Rate of 50.30%. The current 3-Year EPS without NRI Growth Rate is 50.30%, which is 37% above median its 10-year median of 36.70 and 324.5% above the Medical Diagnostics & Research industry median of 11.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Verici Dx (VRCDF), the current 3-Year EPS without NRI Growth Rate is 50.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCDF has been successfully added to your 
